Jubilant Pharmova Ltd (JUBLPHARMA)
₹940.00
Mkt cap
₹14,727 Cr
P/E ratio
38.00
P/B
2.11
Div yield
0.54%
ROE
6.53%
ROCE
8.99%
EPS (TTM)
₹24.74
Book value
₹445
52W range
808–1,181
Sector
Healthcare
Price history
Previous close
Jubilant Pharmova Ltd is an integrated global pharmaceuticals company having three business segments i.e. pharmaceuticals, contract research and development services and proprietary novel drugs. [1]
NSE JUBLPHARMABSE 530019
Health check
Cautious
ValuationFair
ProfitabilityWeak
GrowthLow
TechnicalsBearish
52-week range
−20.42% from high₹940
₹808+16.39% from low₹1,181
Current
₹940.00
Prev close
₹930.00
Day
+1.08%
Price performance
1D
+1.08%
1W
+6.59%
1M
+0.86%
3M
−3.29%
6M
+12.67%
1Y
−9.73%
YTD
−10.93%
Financials
Revenue, profit & margin
P/E ratio
38.0×
JUBLPHARMA is 12% above the sector median of 34.0×
JUBLPHARMA38.0×
Sector median34.0×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,587 | 1,680 | 1,677 | 1,759 | 1,732 | 1,752 | 1,822 | 1,929 | 1,901 | 1,966 | 2,122 | 2,290 | 2,229 | |
| Expenses | 1,419 | 1,438 | 1,459 | 1,487 | 1,480 | 1,463 | 1,535 | 1,584 | 1,611 | 1,625 | 1,833 | 1,951 | 1,981 | |
| Operating Profit | 168 | 242 | 218 | 271 | 252 | 289 | 287 | 345 | 290 | 341 | 289 | 339 | 248 | |
| OPM % | 11% | 14% | 13% | 15% | 15% | 17% | 16% | 18% | 15% | 17% | 14% | 15% | 11% | |
| Other Income | 9 | 19 | 49 | -151 | 410 | 8 | -10 | 9 | 12 | 4 | -19 | 10 | 20 | |
| Interest | 62 | 66 | 71 | 73 | 71 | 61 | 56 | 53 | 49 | 50 | 56 | 56 | 54 | |
| Depreciation | 90 | 97 | 95 | 101 | 91 | 91 | 91 | 95 | 98 | 105 | 121 | 117 | 127 | |
| Profit before tax | 25 | 98 | 101 | -54 | 500 | 144 | 130 | 206 | 154 | 190 | 93 | 176 | 86 | |
| Tax % | 76% | 37% | 34% | 15% | 4% | 29% | 23% | 27% | 34% | 37% | 40% | 32% | 35% | |
| Net Profit | 6 | 62 | 66 | -62 | 482 | 102 | 101 | 151 | 102 | 120 | 56 | 119 | 56 | |
| EPS in Rs | 0.40 | 3.92 | 4.19 | -3.68 | 30.26 | 6.45 | 6.33 | 9.64 | 6.46 | 7.55 | 3.51 | 7.50 | 3.55 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −1.12% · closed higher next day 23 of last 62
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 28 Oct '23◦ | 2 Feb '24◦ | 30 May '24 | 19 Jul '24◦ | 25 Oct '24◦ | 31 Jan '25◦ | 16 May '25◦ | 29 Jul '25 | 31 Oct '25 | 6 Feb '26 | 22 May '26 | 10 Aug '26◦ |
| Earnings day | −4.05% | −1.79% | +0.79% | −3.37% | +3.60% | +0.37% | +1.53% | −1.81% | −1.56% | −3.72% | −0.52% | +0.24% |
| +1 day | −5.71% | −1.91% | −2.56% | −3.38% | +4.74% | −2.32% | +4.62% | +5.29% | +4.60% | −3.21% | −0.43% | −7.49% |
| +5 days | +0.69% | −1.01% | +2.04% | −3.48% | +16.98% | +2.68% | +18.60% | −4.69% | +1.79% | −6.25% | −2.38% | −10.04% |
| +15 days | +8.12% | −2.68% | +1.98% | +13.59% | +6.80% | −0.72% | +20.97% | −7.67% | −3.75% | −11.04% | −2.01% | −5.72% |
| +30 days | +15.19% | −4.18% | +2.21% | +22.33% | +6.28% | −8.57% | +28.02% | −4.22% | −2.91% | −16.19% | −3.25% | — |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Rs 5 Per Share | 5.00 | 24 Jul '26 | 24 Jul '26 |
Shareholding
as of Jun 202647.67%Promoter
Promoters47.67%
FIIs15.87%0.03
DIIs12.40%0.77
Public23.50%0.75
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹1,899.00 | 36.07 | 4,55,634 | 0.84% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| DIVISLAB | ₹9,100.00 | 81.09 | 2,41,576 | 0.33% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| TORNTPHARM | ₹4,857.00 | 82.80 | 1,84,745 | 0.78% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| CIPLA | ₹1,385.00 | 31.26 | 1,11,888 | 0.94% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| ZYDUSLIFE | ₹1,120.00 | 22.95 | 1,11,720 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| LAURUSLABS | ₹1,840.00 | 90.93 | 99,417 | 0.11% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| LUPIN | ₹2,110.00 | 16.20 | 96,483 | 0.85% | 1,417 | +16.08% | 8,277 | +32.04% | 29.93% |
| JUBLPHARMA | ₹924.50 | 37.95 | 14,727 | 0.54% | 56 | −45.09% | 2,229 | +17.29% | 8.99% |
| Median: 158 Co. | ₹421.50 | 33.96 | 2,277 | 0.08% | 13 | +30.25% | 164 | +18.67% | 14.96% |
Filings
Annual reports15
Annual Report 2026bseAnnual Report 2025bseAnnual Report 2024bseAnnual Report 2023bseAnnual Report 2022bseAnnual Report 2021bseAnnual Report 2020bseAnnual Report 2019bseAnnual Report 2018bseAnnual Report 2017bseAnnual Report 2016bseAnnual Report 2015bseAnnual Report 2014bseAnnual Report 2013bseAnnual Report 2012bse
Concall transcripts52
PPTAug 2026TranscriptMay 2026PPTMay 2026PPTFeb 2026PPTOct 2025TranscriptJul 2025PPTJul 2025PPTMay 2025TranscriptFeb 2025PPTFeb 2025PPTJan 2025PPTOct 2024PPTJul 2024PPTMay 2024PPTMay 2024PPTFeb 2024PPTOct 2023PPTJul 2023PPTMay 2023TranscriptFeb 2023TranscriptNov 2022PPTNov 2022TranscriptAug 2022TranscriptJun 2022
Credit ratings6
Announcements5
Receipt Of Show Cause Notice By Jubilant Pharmova Limited - GST 1 Sep - Mysore GST show cause notice proposes Rs.87.31 crore demand for FY2022-23.Announcement under Regulation 30 (LODR)-Newspaper Publication 29 Aug - Newspaper Publication - Relodgement and KYC UpdationReceipt Of Show Cause Notice - Jubilant Generics Limited 28 Aug - CGST Roorkee issued show cause notice on Aug 27, 2026, demanding Rs 52.75 crore GST and equal penalty.Shareholder Meeting / Postal Ballot-Outcome of AGM 26 AugShareholder Meeting / Postal Ballot-Scrutinizer''s Report 26 Aug